6533b833fe1ef96bd129b568
RESEARCH PRODUCT
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
Jenny FurlanettoMarcus SchmidtFrederik MarméPeter KlareMichael UntchPeter A. FaschingVolker MoebusStefanie NoedingAndreas SchneeweissElmar StickelerSabine SchmatlochVolkmar MüllerBruno Valentin SinnWolfgang JanniSibylle LoiblToralf ReimerGunter Von MinckwitzEkkehart LaddaNicole Burchardisubject
0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryNeo adjuvant03 medical and health sciencesRegimen030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinebusinessPathologicalComplete responseEarly breast cancerdescription
568Background: GAIN-2 compares the effectiveness and safety of a predefined idd regimen (EnPC) vs. a dd regimen with modification of single doses depending on individual hematological and non-hemat...
year | journal | country | edition | language |
---|---|---|---|---|
2018-05-20 | Journal of Clinical Oncology |